Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported Net Income Loss of -$7.73 million for the year ending 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed a decrease of -1,251.3% in Net Income Loss from 2024 to 2024.
- This data is from CERO THERAPEUTICS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2022 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: -$1.0 thousand | Q3 2021: $0.00 | Q1 2022: -$378.0 thousand | Q2 2022: -$111.6 thousand | Q3 2022: $84.5 thousand | Q1 2023: -$2.44 million | Q2 2023: -$2.09 million | Q3 2023: -$334.0 thousand | Q1 2024: -$572.2 thousand | Q1 2024: -$1.73 million | Q2 2024: -$2.45 million | Q3 2024: -$4.23 million | Q1 2025: -$5.11 million | Q2 2025: -$5.42 million | Q3 2025: -$4.86 million.
- Over the full 4 years of available data (2022 to 2024), CERO THERAPEUTICS HOLDINGS, INC.'s Net Income Loss has declined by 1,058.0%.
- Historical annual values: Fiscal year 2024: -$7.73 million | Fiscal year 2024: -$572.2 thousand | Fiscal year 2023: -$7.29 million | Fiscal year 2022: -$667.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: